Objective: This study examined the time course of efficacy-related endpoints for lisdexamfetamine dimesylate (LDX) versus placebo in adults with protocol-defined moderate to severe bingeeating disorder (BED).
| I N T R O D U C T I O N
Lisdexamfetamine dimesylate (LDX) is approved for use in adults with moderate to severe binge-eating disorder (BED) in the United States (Vyvanse ® , 2015) . In two large, identically designed, 12-week, dose-optimized, randomized, double-blind, placebo-controlled, Phase 3 studies in adults with protocol-defined moderate to severe BED, dose-optimized LDX (50 or 70 mg/day) produced statistically superior and clinically meaningful reductions in binge eating days/week at weeks 11-12 (primary efficacy endpoint) versus placebo (McElroy et al., 2015a) . In these Phase 3 trials, statistically significant and clinically meaningful improvements on secondary efficacy endpoints were also observed for LDX versus placebo at Week 12/early termination (ET) for including Clinical Global Impressions-Improvement (CGI-I) and 4-week binge eating cessation and at Week 12 for Yale-Brown Obsessive Compulsive Scale modified for Binge Eating (Y-BOCS-BE) and percentage change in body weight (McElroy et al., 2015a) . In a Phase 2, fixed-dose, randomized, double-blind, placebo-controlled trial, LDX (50 and 70 mg but not 30 mg) was also superior to placebo in decreasing binge eating days/week in adults with BED at Week 11 (McElroy et al., 2015b) . In these short-term studies (McElroy et al., 2015a,b) , the safety and tolerability of LDX were generally similar to its established profile for LDX treatment of attention-deficit/hyperactivity disorder (ADHD) (Vyvanse ® , 2015) .
Although the main findings for the primary and key secondary efficacy endpoints from the Phase 3 studies of LDX have been published (McElroy et al., 2015a) , these analyses only examined change from baseline to end of study (Week 12 or Week 12/ET). Statistical assessment of the time course of effects of LDX on efficacy-related endpoints from these studies has not yet been reported. Such data are important because they provide an indication of how soon treatment effects may be anticipated after the therapy is initiated. The current report describes the time course of effects of LDX on efficacy-related endpoints (binge eating days/week, binge eating episodes/week, percentage of participants exhibiting improvement on the dichotomized CGI-I, percentage of participants exhibiting 1-week binge eating response, percentage change in body weight, and Y-BOCS-BE total and subscale score changes) in the two previously described 12-week treatment Phase 3 clinical studies (McElroy et al., 2015a) .
| M E T H O D

| Study design and treatment
Detailed descriptions of study designs and participants have been reported (McElroy et al., 2015a 
| Endpoint measures
Binge eating days/week, binge eating episodes/week, and 1-week binge eating response (percentage reductions in binge eating episodes/ week) data were based on participants' daily self-reported binge eating diaries as assessed and confirmed by experienced and trained clinicians.
Binge eating diaries were assessed at all study visits except screening.
The percentage of participants exhibiting 1-week binge eating responses (reductions in binge-eating episodes/week of 100%, 99-75%, 74-50%, and <50%) was derived at each treatment visit.
The CGI-I (Guy, 1976) Total scores range from 0 to 40. The Y-BOCS-BE, which is a modified version of the Yale-Brown Obsessive Compulsive Scale (Goodman et al., 1989) , has been validated in adults with BED (Deal et al., 2015) .
The Y-BOCS-BE was administered at baseline and Weeks 4, 8, and 12.
Body weight was measured at each visit, and the percentage change from baseline was calculated for each treatment week.
| Data presentation and statistical analyses
Statistically significant findings for the prespecified primary efficacy endpoint (change from baseline in binge eating days/week at Weeks 11-12) and key secondary endpoints (improvement on the dichotomized CGI-I at Week 12/ET, 4-week binge cessation at Week 12/ET, percentage body weight change from baseline at Week 12, and Y-BOCS-BE total score change from baseline at Week 12) have previously been reported (McElroy et al., 2015a) . Time course assessments of efficacy-related endpoints are described in this report.
Statistical assessments were conducted in the full analysis set (participants taking 1 study drug dose and having 1 postbaseline primary efficacy assessment). The time course analyses presented in the current report are analyzed with the same procedures previously described for the prespecified endpoints (McElroy et al., 2015a) . Mixed-effects models for repeated measures analysis over all postbaseline visits, using an unstructured covariance matrix with treatment, visit, and the treatment 3 visit interaction included as factors and baseline score as a covariate and its interaction with visit also included in the model, were used to determine least squares (LS) mean treatment differences (LDX-placebo) in the change from baseline for binge eating days/week, binge-eating episodes/week, percentage body weight change, and Y-BOCS-BE total and domain scores; effects size (ES) size was determined based on the estimated standard deviation from the unstructured covariance matrix.
Degrees of freedom were calculated using the Kenward-Roger approximation method. Treatment comparisons between LDX and placebo in the percentage of participants categorized as improved on the dichotomized CGI-I were analyzed using v 2 tests; odds ratios (ORs) were 
| Improvement on the CGI-I
The percentage of participants categorized as improved on the CGI-I increased over the course of both studies with placebo and LDX (Figure 2A,B) . In both studies, the percentage of participants categorized as improved was greater with LDX than placebo 100% and 99% to 75% in the last 7 days were numerically greater with LDX than placebo from Week 1 to Week 12 in both studies ( Figure 3A ,B).
| Body weight
Mean 6 SD body weight decreased with LDX but not placebo over the course of both studies ( Figure 4A ,B), resulting in larger mean 6 SD percentage decreases in body weight from baseline with LDX than placebo ( Figure 4C,D) . In both studies, the LS mean (95% CI) treatment differences for the percentage body weight change from baseline favored LDX over placebo from 
| Y-BOCS-BE total and domain scores
Mean 6 SD Y-BOCS-BE total scores ( Figure 5A Based on available data from short-term studies for other potential BED therapies, numerically greater reductions in binge eating frequency and body weight for active treatment versus placebo are generally observed within 1-4 weeks of starting treatment (Appolinario et al., 2003; Guerdjikova et al., 2012; Hudson et al., 1998; McElroy et al., 2000 McElroy et al., , 2003 McElroy et al., , 2007 Wilfley et al., 2008) . In one study that reported statistical analysis of treatment effects prior to the end of the study, significantly greater reductions in binge eating days/week and weight for sibutramine versus placebo were reported at treatment Weeks 2 and 4, respectively (Appolinario et al., 2003) .
The study has several limitations. These time course analyses were not prespecified, were not included in the hierarchical testing strategy, and did not account for multiple comparisons. Therefore, all findings related to the time course of effects of LDX are nominal (unadjusted for multiplicity and descriptive in nature). In addition, study participants were mainly women, mainly white, and predominantly met criteria for obesity. Study participants with current comorbid psychiatric disorders that were controlled with prohibited medications or uncontrolled and associated with significant symptoms were also excluded, as were those with histories of psychosis, mania/hypomania, and ADHD (those with mild mood or anxiety symptoms that did not meet diagnostic criteria or require treatment could be included), which may limit the gen- Wang, Duan, & Walsh, 2010) . It would also be of interest to assess the relationship between early treatment response to LDX and longterm outcomes in individuals with BED. However, these analyses were not conducted so the degree to which short-term response to LDX predicts long-term outcomes cannot be determined.
In conclusion, LDX appeared to be associated with improvement in efficacy-related endpoints in adults with protocol-defined moderate to severe BED after 1 week of treatment (after Week 4 [the first assessment] for the Y-BOCS-BE) and these improvements were maintained for the course of the 12-week treatment period. These results suggest that LDX reduces both binge eating behavior and binge eatingrelated psychopathology soon after treatment is initiated. 
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